Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
51.40
+0.25 (0.49%)
At close: Dec 20, 2024, 4:00 PM
52.55
+1.15 (2.24%)
After-hours: Dec 20, 2024, 4:24 PM EST
Corcept Therapeutics Revenue
Corcept Therapeutics had revenue of $182.55M in the quarter ending September 30, 2024, with 47.69% growth. This brings the company's revenue in the last twelve months to $628.56M, up 39.67% year-over-year. In the year 2023, Corcept Therapeutics had annual revenue of $482.38M with 20.04% growth.
Revenue (ttm)
$628.56M
Revenue Growth
+39.67%
P/S Ratio
8.42
Revenue / Employee
$1,785,668
Employees
352
Market Cap
5.39B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 482.38M | 80.52M | 20.04% |
| Dec 31, 2022 | 401.86M | 35.88M | 9.80% |
| Dec 31, 2021 | 365.98M | 12.10M | 3.42% |
| Dec 31, 2020 | 353.87M | 47.39M | 15.46% |
| Dec 31, 2019 | 306.49M | 55.24M | 21.99% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| RadNet | 1.77B |
| Alkermes | 1.51B |
| Merit Medical Systems | 1.33B |
| Stevanato Group | 1.22B |
| Ionis Pharmaceuticals | 803.07M |
| Inspire Medical Systems | 755.59M |
| Tempus AI | 640.44M |
| Telix Pharmaceuticals | 430.80M |
CORT News
- 5 days ago - Corcept's Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism - Business Wire
- 9 days ago - Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing's Syndrome) and Difficult-to-Control Diabetes - Business Wire
- 10 days ago - Corcept Therapeutics' ALS drug fails in mid-stage trial - Reuters
- 10 days ago - Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS) - Business Wire
- 24 days ago - Corcept Therapeutics: A Most Promising And Compelling Biotech - Seeking Alpha
- 7 weeks ago - Corcept Therapeutics Incorporated (CORT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing's Syndrome and Provides Corporate Update - Business Wire
- 2 months ago - Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call - Business Wire